PMID- 35833981
OWN - NLM
STAT- MEDLINE
DCOM- 20220816
LR  - 20220816
IS  - 1432-0584 (Electronic)
IS  - 0939-5555 (Print)
IS  - 0939-5555 (Linking)
VI  - 101
IP  - 9
DP  - 2022 Sep
TI  - An association between a positive direct antiglobulin test and HLA-DR12 in 
      COVID-19.
PG  - 1959-1969
LID - 10.1007/s00277-022-04921-9 [doi]
AB  - SARS-CoV-2 infection has been reported to be associated with a positive direct 
      antiglobulin test (DAT). In this study, an analysis of 40 consecutive coronavirus 
      disease 2019 (COVID-19) cases from December 2020 to September 2021 in Japan 
      revealed that patients of 70 years and over were predisposed to a positive DAT. 
      DAT positivity was related to a decrease in the hemoglobin level. Anemia in 
      DAT-positive COVID-19 patients was attributed to hemolysis, which was 
      corroborated by high reticulocyte counts and an increase in the red blood cell 
      distribution width. Human leukocyte antigen (HLA)-DRB1*12:01 and DRB1*12:02 were 
      exclusively found in DAT-positive COVID-19 patients. In silico assays for the 
      Spike protein of SARS-CoV-2 predicted several common core peptides that met the 
      criteria for a B cell epitope and strong binding to both HLA-DRB1*12:01 and 
      DRB1*12:02. Among these peptides, the amino acids sequence TSNFR, which is found 
      within the S1 subunit of SARS-CoV-2 Spike protein, is shared by human blood group 
      antigen Rhesus (Rh) CE polypeptides. In vitro analysis showed that the expression 
      of HLA-DR in CD4(+) T cells and CD8(+) T cells from a DAT-positive patient was 
      increased after pulsation with TSNFR-sequence-containing peptides. In summary, 
      positive DAT is related to enhanced anemia and to HLA-DR12 in the Japanese 
      population. A peptide sequence within SARS-CoV-2 Spike protein may act as an 
      epitope for IgG binding to RBCs in DAT-positive COVID-19 patients.
CI  - (c) 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, 
      part of Springer Nature.
FAU - Matsuura, Hideaki
AU  - Matsuura H
AD  - Department of Blood Transfusion, Fujita Health University Hospital, 1-98 
      Dengakugakubo, Kutsukake, Toyoake, Aichi, 470-1192, Japan.
AD  - Department of Cellular and Molecular Biology, Fujita Health University School of 
      Medical Sciences, 1-98 Dengakugakubo, Kutsukake, Toyoake, Aichi, 470-1192, Japan.
FAU - Fujii, Sumie
AU  - Fujii S
AD  - Department of Transfusion Medicine and Cell Therapy, Fujita Health University 
      School of Medicine, 1-98 Dengakugakubo, Kutsukake, Toyoake, Aichi, 470-1192, 
      Japan.
FAU - Matsui, Yusuke
AU  - Matsui Y
AD  - Gladstone Institute of Virology and Immunology, University of California, San 
      Francisco, San Francisco, CA, USA.
FAU - Sugiura, Yukari
AU  - Sugiura Y
AD  - Department of Blood Transfusion, Fujita Health University Hospital, 1-98 
      Dengakugakubo, Kutsukake, Toyoake, Aichi, 470-1192, Japan.
FAU - Akiyama, Hidehiko
AU  - Akiyama H
AD  - Department of Cellular and Molecular Biology, Fujita Health University School of 
      Medical Sciences, 1-98 Dengakugakubo, Kutsukake, Toyoake, Aichi, 470-1192, Japan.
FAU - Miura, Yasuo
AU  - Miura Y
AUID- ORCID: 0000-0001-9654-1300
AD  - Department of Blood Transfusion, Fujita Health University Hospital, 1-98 
      Dengakugakubo, Kutsukake, Toyoake, Aichi, 470-1192, Japan. 
      ymiura@fujita-hu.ac.jp.
AD  - Department of Transfusion Medicine and Cell Therapy, Fujita Health University 
      School of Medicine, 1-98 Dengakugakubo, Kutsukake, Toyoake, Aichi, 470-1192, 
      Japan. ymiura@fujita-hu.ac.jp.
LA  - eng
PT  - Journal Article
DEP - 20220714
PL  - Germany
TA  - Ann Hematol
JT  - Annals of hematology
JID - 9107334
RN  - 0 (Epitopes, T-Lymphocyte)
RN  - 0 (HLA-DR Serological Subtypes)
RN  - 0 (HLA-DR12 antigen)
RN  - 0 (Spike Glycoprotein, Coronavirus)
RN  - 0 (spike protein, SARS-CoV-2)
SB  - IM
MH  - CD8-Positive T-Lymphocytes
MH  - *COVID-19
MH  - Coombs Test
MH  - Epitopes, T-Lymphocyte/chemistry
MH  - HLA-DR Serological Subtypes
MH  - Humans
MH  - SARS-CoV-2
MH  - Spike Glycoprotein, Coronavirus
PMC - PMC9281373
OTO - NOTNLM
OT  - COVID-19
OT  - Direct antiglobulin test
OT  - Epitope
OT  - Human leukocyte antigen
OT  - Red blood cell
COIS- The authors declare no competing interests.
EDAT- 2022/07/15 06:00
MHDA- 2022/08/17 06:00
PMCR- 2022/07/14
CRDT- 2022/07/14 11:15
PHST- 2022/03/14 00:00 [received]
PHST- 2022/06/28 00:00 [accepted]
PHST- 2022/07/15 06:00 [pubmed]
PHST- 2022/08/17 06:00 [medline]
PHST- 2022/07/14 11:15 [entrez]
PHST- 2022/07/14 00:00 [pmc-release]
AID - 10.1007/s00277-022-04921-9 [pii]
AID - 4921 [pii]
AID - 10.1007/s00277-022-04921-9 [doi]
PST - ppublish
SO  - Ann Hematol. 2022 Sep;101(9):1959-1969. doi: 10.1007/s00277-022-04921-9. Epub 
      2022 Jul 14.